NCT04913285: A Study to Evaluate KIN-2787 in Subjects With BRAF Mutation Positive Solid Tumors

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: BRAF
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with known active brain metastases; Patients with prior receipt of any BRAF-, MEK-, or MAPK-directed inhibitor therapy

Comments are closed.

Up ↑